Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inmed Pharmaceuticals Inc (NQ: INM )

0.2619 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100
Open 0.2619
Bid (Size) 0.2550 (63)
Ask (Size) 0.2630 (2)
Prev. Close 0.2619
Today's Range 0.2619 - 0.2619
52wk Range 0.2275 - 2.080
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Pinterest Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-32.85%
-32.85%
1 Month
-29.04%
-29.04%
3 Month
-27.23%
-27.23%
6 Month
-43.05%
-43.05%
1 Year
-77.42%
-77.42%

More News

Read More
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board
Via Investor Brand Network
CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies
Via Investor Brand Network
TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day Extension
Via Investor Brand Network
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Numbers for Q2 2024, Corporate Update
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer
Via Investor Brand Network
InMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet Need
Via News Direct
InMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet Need
Via Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones
Via CannabisNewsWire
Why BlackBerry Shares Are Trading Lower By Over 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Approves Election of Directors During 2023 Annual General Meeting
Via Investor Brand Network
Investment Chief At $48B Global X Forecasts AI Stock Dominance In 2024: Unveils Top Investment Opportunities
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
InMed’s (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer’s with a Rare Cannabinoid Analog
Via News Direct
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
InMed's (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer's With A Rare Cannabinoid Analog
Via Benzinga
InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advancing INM-089 to Target Treatment of Age-Related Macular Degeneration
Via Investor Brand Network
TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q1 Fiscal 2024 Financial Results, Provides Business Update
Via Investor Brand Network
Topics Supply Chain
Exposures Supply Chain
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present Phase 2 Study Results for INM-755 at 12th Annual WCI
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.